AutoImmune Inc. is a biopharmaceutical company developing products to treat autoimmune and other cell-mediated inflammatory conditions. Several of these products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

Marligen Biosciences is where researchers go again and again for testing products and services. The company makes nucleic acid purification systems, genetic analysis assays, and other genomics research supplies. Its nucleic acid purification systems include rapid plasma purification systems which are used for isolation DNA so it can mapped, cloned, amplified, labeled, and sequenced. Its genetic analysis assays are sold under the Signet brand name and can screen for certain classes of DNA or be tailored to the researchers needs. Marlingen was acquired by another genetic services provider, OriGene, in 2009.

Eurand, Inc. company, a subsidiary of Netherlands-based Eurand N.V., develops drug delivery technologies to help drugmakers improve the efficacy of their products. Eurand researches and manufactures drugs marketed in the Americas and Europe, mostly through partnerships with other pharma companies. Eurand's drug delivery systems include Biorise to make certain drugs water soluble; Diffucaps and Minitabs to control the release of drug components as they make their way through the digestive system; and AdvaTab and Liquitard to mask the taste of medicines. The company also conducts research for its parent's own portfolio of drugs under development.

Anika Therapeutics, Inc. company was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans; and AMVISC, AMVISC Plus, STAARVISC-II, and ShellGel that are injectable ophthalmic viscoelastic HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. It also provides HYVISC, an HA product used in the treatment of equine osteoarthritis; INCERT, an HA based anti-adhesive for surgical applications; and ORTHOVISC mini, a treatment for osteoarthritis targeting small joints. In addition, the company offers MONOVISC, a single-injection osteoarthritis product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis; and ELEVESS, which is designed as a family of aesthetic dermatology products for facial wrinkles, scar remediation, and lip augmentation. Further, it involves in the research and development of joint health related products, such as a single-injection treatment product that uses a non-animal source HA. Anika Therapeutics, Inc. offers its products in the United States, as well as in Canada, Europe, Turkey, the Middle East, and Asia through representatives, agents, and distributors.

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy’s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

Protein Polymer Technologies, Inc. company was founded in 1988 and is based in San Diego, California. Protein Polymer Technologies, Inc., a biotechnology company, engages in the research, development, and production of bio-active devices to improve medical and surgical outcomes. The company, through its proprietary technology, produces molecular weight polymers that can be processed into a range of material forms, such as gels, sponges, films, and fibers. It also focuses on developing protein polymers that are used in products for tissue augmentation, tissue adhesives and sealants, and drug delivery devices. The company also develops and offers surgical tissue sealants that include tissue adhesives and sealants; wound healing and tissue regeneration products, including fabric dressings, synthetic materials, and biological materials; and urethral bulking agent that relieves female stress incontinence. In addition, it develops coating technology that modifies and improves surface properties of traditional biomedical devices.

Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company’s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.